IBSA was established in Lugano in 1945 and started developing its special identity in 1985 when it was acquired by the current ownership, which adopted a new strategy focused on the acquisition of technological resources and launched a development programme aimed at consolidating its global expansion and developing company assets.

Today IBSA is present in over 90 countries in 5 different continents, with 17 subsidiaries, in Europe, China and the United States and employs more than 2,000 collaborators in its headquarters, subsidiaries and manufacturing sites with a consolidated turnover of CHF 800 million.

IBSA boasts an extensive product portfolio that includes different therapeutic categories, such as prescription drugs, OTC medicines, medical devices and food supplements, and covers 10 therapeutic areas. The company holds 90 patent families and several others in the pipeline.

IBSA’s production lines are characterised by state-of-the-art technology and R&D activities employ latest-generation technologies to optimise the bioavailability, efficacy and safety of existing active substances and supplements in order to develop simpler, more evolved treatment systems.

In fact, over the years IBSA’s Researchers have developed innovative technologies, novel formulations and delivery systems such as softgel capsules, orodispersible films, pre-filled syringes, patches (hydrogel and drug-in-adhesive technologies), gonadotripins purification process, progesterone & ßciclodestrine, single dose strip, Nahyco hybrid technology, device for intravesical instillation.

Thanks to its consolidated experience, its industrial capacity and its proprietary technologies, IBSA is the ideal partner to serve other companies in the pharmaceutical and nutraceutical industry, providing strategic licensing agreements, in countries where it does not operate directly with its subsidiaries, and comprehensive services from drug development through drug manufacturing for EU and non-EU markets.

Read the whole article
Related Articles
A word with Andrea Taborelli – Interview with Chimica Oggi – Chemistry Today
Andrea Toborelli, Business Development and Licensing Manager at IBSA, was interview by Nutra Horizons. 
CPHI October 24-26 Barcelona: IBSA presents cutting-edge technologies to drive pharmaceutical innovation.
As a global pharmaceutical company, IBSA is driven by a distinct vision of care, which starts at the Swiss headquarters and extends globally through continued growth in Europe, Asia, and North America. IBSA’s technologies are aimed at creating more advanced treatment systems to provide healthcare professionals with innovative, effective and reliable therapeutic solutions that improve patients’ quality of life. The product portfolio
Read more
IBSA at CPHI Japan: increase brand awareness and expand presence in the Asian countries
24 MAY 2023 From the 19th to the 21st of April 2023, the CPHI Japan fair was held in Tokyo. An ideal business event for international pharmaceutical professionals to grow their business in the rapidly changing Asian market. IBSA took part in the fair, thus having the opportunity to present its innovations in the pharmaceutical field, presenting new products and
Read more
We’re looking for partners and international distributors for our products.



Via del Piano 29,
6926 Collina d’Oro,
Tel. +41 58 360 10 00




Follow us